Last reviewed · How we verify
NCT02847793: ABMET
Attentional Bias Modification Through Eye-tracker Methodology (ABMET)
NA trial testing Gaze training in Cognitive Deficits in 32 participants. Completed in 28 July 2017.
1 April 2017
Quick facts
| Lead sponsor | Universidad Complutense de Madrid |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 32 |
| Start date | 1 April 2016 |
| Primary completion | 1 April 2017 |
| Estimated completion | 28 July 2017 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Gaze training
- Placebo intervention
Conditions studied
- Cognitive Deficits — all drugs for Cognitive Deficits →
- Depression — all drugs for Depression →
- Alteration of Cognitive Function — all drugs for Alteration of Cognitive Function →
Sponsor
Universidad Complutense de Madrid — full company profile →
Who can join
18 and older, any sex, with Cognitive Deficits or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cognitive biases are a hallmark of depression but there is scarce research on whether these biases can be directly modified by using specific cognitive training techniques. The aim of this study will be targeting and modifying specifically relevant attention biases in participants with subclinical depression using eye-tracking methodologies. This innovative approach has been proposed as a promising future line of intervention in Attention Bias Modification procedures (Koster \& Hoorelbeke, 2015). Recent findings suggest that depression is characterized by a double attentional bias (Duque \& Vazquez, 2015), More specifically, depressed individuals have difficulties both to disengage from negative materials (e.g., sad faces) and to engage with positive materials (e.g., happy faces). Thus, training procedures to change attentional biases should target these two separate components.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Attentional bias modification in depression through gaze contingencies and regulatory control using a new eye-tracking intervention paradigm: study protocol for a placebo-controlled trial.
Vazquez C, Blanco I, Sanchez A, McNally RJ. · · 2016 · cited 20× · PMID 27931196 · DOI 10.1186/s12888-016-1150-9
Verify or expand the search:
- PubMed search for NCT02847793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gaze training
Trials testing the same drug.
- NCT04426227 — Gaze Training on Task Performance Regional Anaesthesia · Phase 3 · unknown
Other recruiting trials for Cognitive Deficits
Currently open trials in the same condition.
- NCT07111169 — Neuromodulation and Attention Deficits in MDD · NA · recruiting
Other Universidad Complutense de Madrid trials
Trials by the same sponsor.
- NCT07361848 — Long-Hold Yielding Isometric Exercise for Patellar Tendinopathy in Weightlifting Athletes · NA · not yet recruiting
- NCT07273006 — Percutaneous Electrical Nerve Stimulation As Alternative To Nerve Blocks In Anesthesia, Pain Medicine And Rehabilitation · Phase 4 · not yet recruiting
- NCT07527351 — ANALYSIS OF THE RELIABILITY AND VALIDITY OF LASER SPECKLE CONTRAST IMAGING · NA · recruiting
- NCT07484620 — Physical Activity and Fitness in Pediatric Inflammatory Bowel Disease · NA · not yet recruiting
- NCT07485400 — Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02847793 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Complutense de Madrid
- Last refreshed: 10 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02847793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing